Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosisSOUTH SAN ...
Presentation of encouraging preclinical results for CER-1236 in ovarian cancer, indicating potential effectiveness of the treatment. No observed toxicity in animal models after treatment, highlighting ...
CALGARY, AB, Feb. 25, 2026 /CNW/ - The Canada Energy Regulator (CER) has launched the CER Portal, a secure, one‑window access point for certain regulatory filings. The Portal improves how the CER ...
CERo Therapeutics Holdings, Inc. has announced that TriStar Centennial Medical Center in Nashville, Tennessee, will serve as a clinical trial site for its Phase 1 clinical study of CER-1236, a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results